
BiotechTV - News
BiotechTVAudio
- Format:
- Podcast
- New episodes:
- Several times a week
- Typical length:
- about 10 minutes
- Latest episode:
About this show
This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.
Covers: biotechnology, pharmaceutical industry, biotech investing, clinical trials, drug approval, gene editing, neurodegenerative disease, immunology drugs
Show details and episodes come from the publisher's public feed at anchor.fm. Last updated . Names, artwork and text belong to their publishers.
Recently on this show
Summary of recent episodes, drawn from the publisher's feed.
BiotechTV's news feed offers on-the-ground reports from biotech hubs around the world. Recent episodes cover Jefferies London 2026 interviews with executives from Protagonist, Valneva, Generate Biomedicines and Intellia, plus Nektar's atopic dermatitis work and Sofinnova's new European fund.
Cosmos
Similar in subject
- Pharmaceutical Executive
Both cover: drug approval, pharmaceutical industry, clinical trials - Biotech Hangout
Both cover: biotech investing, clinical trials - BioTech Nation ... with Dr. Moira Gunn
Both cover: pharmaceutical industry, biotechnology
Similar shows
Explore more
Episodes
London based IMU Biosciences announced today that it will use its immune system profiling platform with 80,000 blood samples from UK Biobank to create a large-scale picture of the human immune system
· 13 min
CEO John Baker describes how the project, done in collaboration with Ultima Genomics and Waters Corporation, will give researcher a tool to better understand the immune system. He also describes how IMU's blood sample based system works, and how it has been used for things such as to better understand which patients will respond to cancer immunotherapies.
Not rated yetOxford, UK based OMass Therapeutics announced a $310M series C today, advancing its small molecule platform, including the lead MC2 (melanocortin-2) receptor antagonist that is in phase 1
· 11 min
CEO Ros Deegan describes the raise and the new investors that it brings into the company, and updates us on the company's pipeline progress.
Not rated yetAt Dana-Farber Cancer Institute in Boston, President & CEO Ben Ebert and Professor and Investigator Cigall Kadoch discuss the latest trends in cancer research
· 19 min
They discuss recent advances, what's ahead, Cigall's work in epigenetics, and how a new hospital will be purpose built for patients with the best new technologies in clinical research.
Not rated yetEli Lilly Chairman & CEO David Ricks discusses GLP-1's, Alzheimer's, business development and more
· 23 min
From the company's headquarters in Indianapolis, he describes where he thinks the obesity field could be headed in the next few years, what might be next after beta-amyloid in Alzheimer's, and how he plans to invest for the future.
Not rated yetAfter a busy time in Boston during the Aging Research and Drug Discovery Meeting, Insilico Medicine CEO Alex Zhavoronkov discusses the latest in longevity therapeutics and Insilico's pipeline progress
· 27 min
He describes the biomarkers that researchers and investigators have been using, and how large pharma companies like Lilly and Novo Nordisk have begun to embrace the field. Plus, the logevity component Insilico has built into its IPF trials, and what other programs and targets he calls out.
Not rated yetMonte Rosa Therapeutics announced data for MRT-8102, its NEK7-directed molecular glue degrader, showing positive impact on biomarkers linked to atherosclerotic cardiovascular disease
· 20 min
CEO Markus Warmuth walks us through the data and provides a broader update on the pipeline progress at Monte Rosa and for the field of degraders and molecular glues more broadly.
Not rated yetFrom Basel: TOLREMO Therapeutics is working on cancer resistance - the company believes is targeting CBP/p300 just stared phase 1 data at World Lung
· 7 min
CEO Stefanie Fluckiger-Mangual describes the rationale for targeting CPB/p300 and walks us through TOLREMO's recently presented phase 1 data, which had a clean safety profile and showed evidence of anti-tumor activity.
Not rated yetFrom Basel: Forty51 Ventures was formed in Basel four years ago and has a company building model - they look globally, but believe that having the pharma company pipeline in Basel is an advantage
· 9 min
Co-Founder & Partner Sascha Oliver Bucher describes the firm and investments it has been making, and shares his thoughts on the VC ecosystem in Europe.
Not rated yetFrom Basel: With two products on the market with momentum and a key pipeline asset in a P3, Basilea has become a world leader in the development of therapies for bacterial and fungal infections
· 13 min
CEO David Veitch discusses Cresemba and Zevtera, both of which have momentum in what used to be market with structural barriers to commercial success, but no longer are in most geographies. Plus, a key phase 3 that will read out for Basilea's next mold infection program, fosmanogepix, in 2028.
Not rated yetBeacon Therapeutics' gene therapy for X-linked retinitis pigmentosa succeeded on its primary endpoint of helping patients to see better on low luminance visual acuity in a phase three study
· 9 min
Chris Hollowood, Founder of Beacon and CEO of Syncona, describes the top line result and its significance. This is the first pivotal trial in X-linked retinitis pigmentosa to achieve its primary endpoint.
Not rated yet